Evaluation of efficiency and safety of dapagliflozin in treating of type 2 diabetes mellitus
Not Applicable
- Conditions
- type 2 diabetes
- Registration Number
- JPRN-UMIN000023681
- Lead Sponsor
- Juntendo University Urayasu Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1.Type 1 diabetes mellitus 2.Diabetic ketoacidosis, diabetic coma, or before coma 3.Sever infection, before and not long after surgery, or patients with sever trauma 4.Left ventricular dysfunction (EF < 50%) 5.Sever liver dysfunction 6.Past history of cerebral infarction, myocardial infarction, and sever heart failure 7.Women suspected of pregnancy or pregnant 8.Patients with a history of use SGLT2 inhibitors 9.Patients who have repeated urinary tract infections 10.Alchole intake excessive 11.Inadequate patients judged by doctor
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Amount of change in HbA1c after administration 24 weeks later
- Secondary Outcome Measures
Name Time Method Body weight Blood pressure Serum lipid heart function (LVEF, E/A, E/e', DcT, LVMI,LAV) Urinary albumin excretion Urinary L-FABP excretion, serum cystatinC,eGFR Liver function(AST,ALT,gammaGTP)